Torrent Pharmaceuticals Ltd management interview: Torrent Pharma Q2 Interview: Semaglutide, Margins, Brazil & Synergy Targets Explained | Sudhir Menon
ET Now, 2026-10-26. Video: https://www.youtube.com/watch?v=CpaJeWsU2WY
- Earnings drivers: EBITDA growth benefited from the prior-year comparison excluding JB numbers, while acquisition-related amortization and interest costs weighed on profit. Once the new cost base is fully reflected this year, management expects PAT growth to exceed EBITDA growth from next year.
- India and semaglutide: India grew 20% against market growth of 12%, with volume and price growth each at 7.5%. Torrent guided to ₹200 to ₹250 crore of semaglutide revenue this year and expects prices to remain stable, with most relevant competition already in the market after 6 months.
- Margins and synergies: Q2 EBITDA margin was 33.5%, and H2 is expected to be a little higher. JB cost synergies of ₹450 crore are tracking ahead of plan: management said 50% is being realized this year and the balance 50% should come next year, with the full amount expected by end of FY28.
- Brazil outlook: Underlying Brazil growth is expected to be 13 to 15% over the next 3 years; Q2’s strong growth partly made up for lower Q1 primary sales during a secondary-inventory correction. Approval for the Ozempic version in Brazil is expected by Q4 or Q1 of next year.
- FY28 growth: Management expects FY28 growth to be strong and better than FY27, with JB growth returning from Q3 onwards and the base business continuing to grow strongly.